TRCT
CTOR

Tower Research Capital (TRC)’s Citius Oncology CTOR Stock Holding History

Tower Research Capital (TRC)’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-11,846
Closed -$24K – 5709
2025
Q3 		$24K Buy
+11,846
New +$25.7K ﹤0.01% 3138
2025
Q1 		– Sell
-41
Closed -$47 – 5936
2024
Q4 		$47 Hold
41
– – ﹤0.01% 5549
2024
Q3 		$57 Hold
41
– – ﹤0.01% 5558
2024
Q2 		$466 Hold
41
– – ﹤0.01% 5321
2024
Q1 		$453 Sell
41
-34
-45% -$374 ﹤0.01% 5484
2023
Q4 		$820 Sell
75
-5
-6% -$54 ﹤0.01% 5491
2023
Q3 		$862 Sell
80
-4
-5% -$43 ﹤0.01% 5455
2023
Q2 		$885 Buy
+84
New +$878 ﹤0.01% 5524

Other funds holding CTOR

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OAC
OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tower Research Capital (TRC)'s CTOR Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Citius Oncology (CTOR) in Q4 2025, closing a stake of 11,846 shares — an estimated $24K sold.

Tower Research Capital (TRC) first reported a position in CTOR in Q2 2023 and held it in 8 quarters. The position peaked at $24K in Q3 2025. 18 funds tracked by Wall St. Rank hold CTOR as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Citius Oncology position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 11,846 Citius Oncology shares in Q4 2025, an estimated $24K.
  • Tower Research Capital (TRC) first reported a position in Citius Oncology in Q2 2023 and held it in 8 quarters.
  • Tower Research Capital (TRC)'s Citius Oncology position peaked at $24K in Q3 2025.
  • 18 funds tracked by Wall St. Rank held Citius Oncology as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.